Current Clinical Applications of In Vivo Gene Therapy with AAVs
2020 · Molecular Therapy · 703 citations
https://doi.org/10.1016/j.ymthe.2020.12.007
J
Jacques P. Tremblay
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
393
Papers
12.7K
Citations
57
h-index
224
i10-index
Jacques P. Tremblay is an academic researcher from Laval Mayenne Technopole. The author has contributed to research in topics: Muscle Physiology and Disorders & CRISPR and Genetic Engineering & Mesenchymal stem cell research. The author has an h-index of 57, co-authored 335 publications.
ORCID: 0000-0001-9404-9195Papers by this author
worksReading Frame Correction by Targeted Genome Editing Restores Dystrophin Expression in Cells From Duchenne Muscular Dystrophy Patients
2013 · Molecular Therapy · 174 citations
https://doi.org/10.1038/mt.2013.111
Prevention by anti-LFA-1 of acute myoblast death following transplantation
1997 · The Journal of Immunology · 135 citations
https://doi.org/10.4049/jimmunol.159.5.2522
Efficient Restoration of the Dystrophin Gene Reading Frame and Protein Structure in DMD Myoblasts Using the CinDel Method
2016 · Molecular Therapy — Nucleic Acids · 79 citations
https://doi.org/10.1038/mtna.2015.58
An AAV9 coding for frataxin clearly improved the symptoms and prolonged the life of Friedreich ataxia mouse models
2014 · Molecular Therapy — Methods & Clinical Development · 51 citations
https://doi.org/10.1038/mtm.2014.44
Targeted Gene Addition of Microdystrophin in Mice Skeletal Muscle via Human Myoblast Transplantation
2013 · Molecular Therapy — Nucleic Acids · 23 citations
https://doi.org/10.1038/mtna.2012.55
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat